Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: M.S.H who wrote (1092)	6/3/1998 10:43:00 AM
From: Jeffrey L. Henken	Respond to of 2887

"Also,we do not believe this purchase will necessarily alter AVE'S plans for other acquisitions." How about we discuss more recent evidence that American BioMed could be a potential acquisition target. Here are some interesting comments on the AVEI acquisition of World Medical. Well let me paste it here and if anyone has any desire to discuss this please put your two cents in: Dain Rauscher Wessels 12:59 AVEI STRONG BUY !!!!!!!! Apr 13 1998 2:26PM EDT * We view the Acq. as a favorable event. Ave has acknowledged its intent to acquire new businesses(to complement various internal projects)in establishing itself as a full vascular company. This move provides assurance of the company's commitment to this strategy. While the AAA platform will provide less leverage to AVE's large coronary stent business over the short to immediate term,it represents a very attractive and necessary opportunity longer-term as the stent market matures. Importantly, AVE was able to obtain World Medical at a relatively inexpensive price compared with the $75 million and $ 85 million acq. of competitors AneuRx(Medtronic) and Corvita (Pfizer),respectively. ,b>Also,we do not believe this purchase will necessarily alter AVE'S plans for other acquistions. The Talent AAA stent graft represents a revolutionary treatment approach over conventional surgical techniques. AAA ia a fatal disease diagnosed in nearly 200,000 Americans every year,with 45,000 patients undergoing open surgery.Endovascular repair of AAA using grafts is an emerging minimally invasive approach that continues to gain acceptance in Europe, where 2,500 implants took place last year.The competitive landscape is crowded, with most large cardio. players now welding a AAA product. World Medical addresses this area with the Talent self-expanding stent design that incorporates an important two-piece("pantleg") design for bifurcated aneursyms and is similar in concept to both the medtronic AneuRX an Boston Scientific Vanguard devices. The Talent system has been implanted in more than 600 patients worldwide and is in Phase II clinical trials in the U.S.,the most significant market ,in our opinion. THE MOST DISTINGUISHING FEATURE OF THE TALENT SYSTEM IS THAT IT IS THE ONLY DEVICE THAT CAN BE IMPLANTED ABOVE THE RENAL ARTERIES-A FEATURE THAT WE BELIEVE WILL BE CRITICAL IN THE FUTURE. *** SIX-MONTH PRICE TARGET $ 51.00 P/E Mulitiple of 30 calendar 1998 EPS estimate of $ 1.70 I think American BioMed's broader product line makes them a very attractive acquisition candidate. Well folks there you have it. AVEI may not even be done buying companies and they got a great deal on World Medical! Now I am certainly not saying American BioMed is about to be bought by anyone but..... In the event of a buy out what would American BioMed go for? Regards, Jeff